WO2008060546A3 - Oral formulations - Google Patents

Oral formulations Download PDF

Info

Publication number
WO2008060546A3
WO2008060546A3 PCT/US2007/023862 US2007023862W WO2008060546A3 WO 2008060546 A3 WO2008060546 A3 WO 2008060546A3 US 2007023862 W US2007023862 W US 2007023862W WO 2008060546 A3 WO2008060546 A3 WO 2008060546A3
Authority
WO
WIPO (PCT)
Prior art keywords
oral formulations
disclosed
pharmaceutical composition
composition containing
oral administration
Prior art date
Application number
PCT/US2007/023862
Other languages
French (fr)
Other versions
WO2008060546A2 (en
Inventor
Ronald S Vladyka
David C Dalgarno
John D Iuliucci
Original Assignee
Ariad Gene Therapeutics Inc
Ronald S Vladyka
David C Dalgarno
John D Iuliucci
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ariad Gene Therapeutics Inc, Ronald S Vladyka, David C Dalgarno, John D Iuliucci filed Critical Ariad Gene Therapeutics Inc
Priority to EP07870878.1A priority Critical patent/EP2094241A4/en
Priority to CA002669415A priority patent/CA2669415A1/en
Priority to AU2007319825A priority patent/AU2007319825B2/en
Priority to JP2009537189A priority patent/JP2010509400A/en
Publication of WO2008060546A2 publication Critical patent/WO2008060546A2/en
Publication of WO2008060546A3 publication Critical patent/WO2008060546A3/en
Priority to IL198760A priority patent/IL198760A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

A solid pharmaceutical composition containing AP23573 suitable for oral administration is disclosed.
PCT/US2007/023862 2006-11-14 2007-11-14 Oral formulations WO2008060546A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP07870878.1A EP2094241A4 (en) 2006-11-14 2007-11-14 Oral formulations
CA002669415A CA2669415A1 (en) 2006-11-14 2007-11-14 Solid dosage form comprising ap23573
AU2007319825A AU2007319825B2 (en) 2006-11-14 2007-11-14 Oral formulations
JP2009537189A JP2010509400A (en) 2006-11-14 2007-11-14 Oral formulation
IL198760A IL198760A0 (en) 2006-11-14 2009-05-14 Oral formulations

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85887006P 2006-11-14 2006-11-14
US60/858,870 2006-11-14

Publications (2)

Publication Number Publication Date
WO2008060546A2 WO2008060546A2 (en) 2008-05-22
WO2008060546A3 true WO2008060546A3 (en) 2009-04-30

Family

ID=39402236

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/023862 WO2008060546A2 (en) 2006-11-14 2007-11-14 Oral formulations

Country Status (8)

Country Link
US (3) US20080161335A1 (en)
EP (1) EP2094241A4 (en)
JP (2) JP2010509400A (en)
CN (2) CN103330694A (en)
AU (1) AU2007319825B2 (en)
CA (1) CA2669415A1 (en)
IL (1) IL198760A0 (en)
WO (1) WO2008060546A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8852590B2 (en) 2009-04-16 2014-10-07 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer
CN102499929B (en) * 2011-09-29 2014-10-08 福建省微生物研究所 42-(Dimethylphosphinate)rapamycin solid composition and coating method thereof
NZ629486A (en) * 2013-05-29 2017-11-24 Signal Pharm Llc Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use
BR112019027402A2 (en) 2017-06-22 2020-07-07 Celgene Corporation treatment of hepatocellular carcinoma characterized by infection with the hepatitis b virus
CN110876730A (en) * 2019-12-06 2020-03-13 怀化正好制药有限公司 Fukangning tablet and its preparation method

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040077677A1 (en) * 2002-09-17 2004-04-22 Wyeth Oral formulations
US20040254210A1 (en) * 2001-09-28 2004-12-16 Barbara Haeberlin Pharmaceutical compositions comprising colloidal silicon dioxide
US20060094745A1 (en) * 2004-10-28 2006-05-04 Wyeth Use of an mTOR inhibitor in treatment of uterine leiomyoma

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206018A (en) * 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
JPS6390534A (en) 1986-10-06 1988-04-21 Hitachi Ltd Alkali-soluble ladder silicone polymer
JPS63101427A (en) 1986-10-17 1988-05-06 Hitachi Ltd Alkali-soluble ladder silicone
US6146358A (en) * 1989-03-14 2000-11-14 Cordis Corporation Method and apparatus for delivery of therapeutic agent
WO1990013332A1 (en) 1989-05-11 1990-11-15 Cedars-Sinai Medical Center Stent with sustained drug delivery
DK0441516T3 (en) * 1990-02-08 1995-06-12 Howmedica Inflatable catheter
US5545208A (en) * 1990-02-28 1996-08-13 Medtronic, Inc. Intralumenal drug eluting prosthesis
US5378696A (en) * 1990-09-19 1995-01-03 American Home Products Corporation Rapamycin esters
JPH06502536A (en) 1990-10-09 1994-03-24 メルク　エンド　カンパニー　インコーポレーテッド Novel biological phosphorylation method for organic compounds
US5604294A (en) * 1991-09-05 1997-02-18 Luly; Jay R. Macrocyclic immunomodulators
US5252732A (en) * 1991-09-09 1993-10-12 Merck & Co., Inc. D-heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and O-alkynylheteroarylmacrolides having immunosuppressive activity
US5516781A (en) * 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
US5599352A (en) * 1992-03-19 1997-02-04 Medtronic, Inc. Method of making a drug eluting stent
US5283257A (en) * 1992-07-10 1994-02-01 The Board Of Trustees Of The Leland Stanford Junior University Method of treating hyperproliferative vascular disease
MX9304868A (en) 1992-08-13 1994-05-31 American Home Prod 27-HYDROXYRAPAMICINE, DERIVED FROM THE SAME AND PHARMACEUTICAL COMPOSITION THAT CONTAINS IT.
US5434260A (en) * 1992-10-13 1995-07-18 American Home Products Corporation Carbamates of rapamycin
US5489680A (en) * 1992-10-13 1996-02-06 American Home Products Corporation Carbamates of rapamycin
US5310903A (en) * 1993-03-05 1994-05-10 Merck & Co., Inc. Imidazolidyl rapamycin derivatives
WO1994025022A1 (en) 1993-04-23 1994-11-10 Abbott Laboratories Rapamycin conjugates and antibodies
US5464650A (en) * 1993-04-26 1995-11-07 Medtronic, Inc. Intravascular stent and method
US5387680A (en) * 1993-08-10 1995-02-07 American Home Products Corporation C-22 ring stabilized rapamycin derivatives
US5391730A (en) * 1993-10-08 1995-02-21 American Home Products Corporation Phosphorylcarbamates of rapamycin and oxime derivatives thereof
US5385910A (en) * 1993-11-22 1995-01-31 American Home Products Corporation Gem-distributed esters of rapamycin
US6152141A (en) * 1994-07-28 2000-11-28 Heartport, Inc. Method for delivery of therapeutic agents to the heart
US5660873A (en) * 1994-09-09 1997-08-26 Bioseal, Limited Liability Corporaton Coating intraluminal stents
JP3942201B2 (en) 1994-11-18 2007-07-11 株式会社カネカ Method for producing phenylpolysilsesquioxane
US5491231A (en) * 1994-11-28 1996-02-13 American Home Products Corporation Hindered N-oxide esters of rapamycin
US5665591A (en) * 1994-12-06 1997-09-09 Trustees Of Boston University Regulation of smooth muscle cell proliferation
JP3324360B2 (en) * 1995-09-25 2002-09-17 信越化学工業株式会社 Polysiloxane compound and positive resist material
CA2199890C (en) * 1996-03-26 2002-02-05 Leonard Pinchuk Stents and stent-grafts having enhanced hoop strength and methods of making the same
US6273913B1 (en) * 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
US5780604A (en) * 1997-09-26 1998-07-14 Abbott Laboratories 11,12-cyclic phosphite or phosphate derivatives of erythromycin and related macrolides
US6623521B2 (en) 1998-02-17 2003-09-23 Md3, Inc. Expandable stent with sliding and locking radial elements
US20010029351A1 (en) 1998-04-16 2001-10-11 Robert Falotico Drug combinations and delivery devices for the prevention and treatment of vascular disease
WO1999063929A2 (en) * 1998-06-08 1999-12-16 Advanced Medicine, Inc. Multibinding inhibitors of microsomal triglyceride transferase protein
US6153252A (en) * 1998-06-30 2000-11-28 Ethicon, Inc. Process for coating stents
US6087064A (en) * 1998-09-03 2000-07-11 International Business Machines Corporation Silsesquioxane polymers, method of synthesis, photoresist composition, and multilayer lithographic method
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
CA2374944A1 (en) 1999-06-10 2000-12-21 Nigel Hacker Spin-on-glass anti-reflective coatings for photolithography
US6890448B2 (en) 1999-06-11 2005-05-10 Shipley Company, L.L.C. Antireflective hard mask compositions
JP4187879B2 (en) 1999-08-06 2008-11-26 東京応化工業株式会社 Radiation sensitive resist composition
AU2599501A (en) 1999-12-29 2001-07-09 Advanced Cardiovascular Systems Inc. Device and active component for inhibiting formation of thrombus-inflammatory cell matrix
GB0000482D0 (en) 2000-01-11 2000-03-01 Norton Healthcare Ltd Enteric coated pharmaceutical formulation
ATE307625T1 (en) 2000-05-12 2005-11-15 Cordis Corp DRUG DELIVERY SYSTEMS FOR THE TREATMENT OF VASCULAR DISEASES
US6776796B2 (en) 2000-05-12 2004-08-17 Cordis Corportation Antiinflammatory drug and delivery device
JP4622061B2 (en) 2000-07-27 2011-02-02 Ｊｓｒ株式会社 Composition for resist underlayer film and method for producing the same
TW556047B (en) 2000-07-31 2003-10-01 Shipley Co Llc Coated substrate, method for forming photoresist relief image, and antireflective composition
JP4141625B2 (en) 2000-08-09 2008-08-27 東京応化工業株式会社 Positive resist composition and substrate provided with the resist layer
US20030033007A1 (en) 2000-12-22 2003-02-13 Avantec Vascular Corporation Methods and devices for delivery of therapeutic capable agents with variable release profile
BR0208627A (en) 2001-04-06 2004-03-09 Wyeth Corp Antineoplastic combinations such as rapamycin together with gemcitabine or fluorouracil
TW594416B (en) 2001-05-08 2004-06-21 Shipley Co Llc Photoimageable composition
TW200730152A (en) * 2002-01-10 2007-08-16 Novartis Ag Drug delivery systems for the prevention and treatment of vascular diseases
US20030220297A1 (en) 2002-02-01 2003-11-27 Berstein David L. Phosphorus-containing compounds and uses thereof
US7432277B2 (en) 2002-02-01 2008-10-07 Araid Gene Therapeutics, Inc. Phosphorus-containing macrocycles
JP4557497B2 (en) 2002-03-03 2010-10-06 ローム・アンド・ハース・エレクトロニック・マテリアルズ，エル．エル．シー． Method for producing silane monomer and polymer and photoresist composition comprising the same
EP1648900A4 (en) 2003-07-11 2010-02-10 Ariad Pharma Inc Phosphorus-containing macrocycles
JP2007502807A (en) 2003-08-18 2007-02-15 ファイザー・プロダクツ・インク ERBB2 anticancer drug administration schedule
AR045957A1 (en) * 2003-10-03 2005-11-16 Novartis Ag PHARMACEUTICAL COMPOSITION AND COMBINATION
GB0327840D0 (en) 2003-12-01 2003-12-31 Novartis Ag Organic compounds
EP1809276A4 (en) * 2004-09-30 2009-06-17 Ariad Pharma Inc Treatment method
WO2006069038A1 (en) 2004-12-20 2006-06-29 Ariad Gene Therapeutics, Inc. Therapeutic materials and methods
US20060160837A1 (en) * 2004-12-29 2006-07-20 The Brigham And Women's Hospital, Inc. Rapamycin compounds in the treatment of neurofibromatosis type 1
CN101119709A (en) 2005-02-15 2008-02-06 惠氏公司 Orally bioavailable cci-779 formulations
US20070004767A1 (en) 2005-06-30 2007-01-04 Gutmann David H Methods for treating neurofibromatosis 1
US20070105887A1 (en) 2005-11-04 2007-05-10 Wyeth Antineoplastic combinations of temsirolimus and sunitinib malate
EA015922B1 (en) * 2005-11-14 2011-12-30 Ариад Фармасьютикалз, Инк. Administration of mtor inhibitor to treat patients with cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040254210A1 (en) * 2001-09-28 2004-12-16 Barbara Haeberlin Pharmaceutical compositions comprising colloidal silicon dioxide
US20040077677A1 (en) * 2002-09-17 2004-04-22 Wyeth Oral formulations
US20060094745A1 (en) * 2004-10-28 2006-05-04 Wyeth Use of an mTOR inhibitor in treatment of uterine leiomyoma

Also Published As

Publication number Publication date
US20130202702A1 (en) 2013-08-08
JP2010509400A (en) 2010-03-25
JP2014040462A (en) 2014-03-06
AU2007319825A1 (en) 2008-05-22
US20100247643A1 (en) 2010-09-30
CN103330694A (en) 2013-10-02
CA2669415A1 (en) 2008-05-22
WO2008060546A2 (en) 2008-05-22
EP2094241A4 (en) 2013-04-17
CN101583347A (en) 2009-11-18
US20080161335A1 (en) 2008-07-03
IL198760A0 (en) 2010-02-17
EP2094241A2 (en) 2009-09-02
AU2007319825B2 (en) 2014-01-23
US8496967B2 (en) 2013-07-30

Similar Documents

Publication Publication Date Title
AU2007295179A1 (en) Dosage unit for sublingual, buccal or oral administration of water-insoluble pharmaceutically active substances
ZA200605631B (en) Directly compressible pharmaceutical composition for the oral administration of CCI-779
HK1091114A1 (en) Solid pharmaceutical compositions comprising a s1p receptor agonist and a sugar alcohol
WO2006127738A3 (en) Compressible chewing gums for delivery of actives
WO2007121318A3 (en) Formulations for delivering insulin
EP2112925A4 (en) Solid pharmaceutical dosage formulations
WO2007016284A3 (en) Pharmaceutical formulations/composition of guanfacine suitable for single dose form adminstration daily
WO2007075794A3 (en) Oral formulations comprising tigecycline
AU2003246978A1 (en) Pharmaceutical compositions comprising cyclosporin for oral administration
EP2226071A4 (en) Composition for oral administration
EP2062579A4 (en) Solid pharmaceutical composition for oral administration comprising optically stable ramosetron
EP1941896A4 (en) Dipeptide-containing composition for oral administration
IL164440A0 (en) New pharmaceutical composition containing fibanserin polymorph a
EP1811967A4 (en) Methods and formulations for making pharmaceutical compositions containing bupropion
WO2007131070A3 (en) Compositions, dosage forms and methods of treating emesis
EP2206519A4 (en) Medicinal preparation for oral administration
WO2008060546A3 (en) Oral formulations
WO2009060064A3 (en) Pharmaceutical formulations for the oral administration of ppi
WO2010079433A3 (en) Pharmaceutical composition comprising melogliptin
HK1102021A1 (en) Pharmaceutical composition for oral administration of a pyrazol-3- carboxamide derivative
WO2008079629A3 (en) Formulations with improved bioavailability
EP1626697A4 (en) Pharmaceutical compositions for oral administration comprising lithium carbonate
HK1092734A1 (en) Oral formulation for twice-daily administration
ZA201102405B (en) Pharmaceutical composition for oral administration
WO2007096733A3 (en) Desloratadine-containing formulation stabilized with cyclodextrin

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780042435.0

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07870878

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2007319825

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2669415

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2009537189

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 198760

Country of ref document: IL

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 1930/KOLNP/2009

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2007319825

Country of ref document: AU

Date of ref document: 20071114

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2007870878

Country of ref document: EP